KASID
Search
- Page Path
- HOME > Search
Review
- IBD
- Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review
- Eron Fabio Miranda, Rodrigo Bremer Nones, Paulo Gustavo Kotze
- Intest Res 2021;19(3):255-264. Published online November 6, 2020
- DOI: https://doi.org/10.5217/ir.2020.00029
-
Abstract
PDF
PubReader
ePub - With the overspread use of measurement of serum levels of anti-tumor necrosis factor (TNF) agents (therapeutic drug monitoring, TDM), new therapeutic strategies have been used in the management of Crohn’s disease (CD). Different targets are correlated with increased levels of circulating drugs. Recent evidence demonstrated that higher serum levels of anti-TNF agents may be associated to better outcomes in perianal fistulizing CD (PFCD). Overall, patients with healed fistulas had higher serum levels of infliximab and adalimumab as compared to those with active drainage. This was demonstrated in some cohort studies, in induction and maintenance, in adults and children with PFCD. In this narrative review, authors summarize current evidence on the use of serum level measurement of anti-TNF agents and its correlation with perianal fistula healing in CD patients. Data on the use of TDM in PFCD is discussed in detail. The retrospective design of the studies and the lack of objective parameters to measure fistula healing are the main limitations of published data. Prospective studies, with central reading of objective radiological parameters, such as pelvic magnetic resonance imaging scores, can improve the level of evidence on the possible advantages of TDM in perianal fistula in CD and are warranted.
-
Citations
Citations to this article as recorded by
- Management of Perianal Fistulizing Crohn’s Disease
Arshdeep Singh, Vandana Midha, Gursimran Singh Kochhar, Bo Shen, Ajit Sood
Inflammatory Bowel Diseases.2024; 30(9): 1579. CrossRef - Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature
Maria P Vallejo, Arturo P Jaramillo, Carlos Luis Guanín Cabrera, Maria G Cueva, Mario Navarro Grijalva, Xavier Grandes
Cureus.2024;[Epub] CrossRef - Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
Journal of Clinical Gastroenterology.2023; 57(6): 601. CrossRef - Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber
Gut and Liver.2023; 17(3): 430. CrossRef - Therapeutic Drug Monitoring in Perianal Fistulizing Crohn’s Disease
Mir Zulqarnain, Parakkal Deepak, Andres J. Yarur
Journal of Clinical Medicine.2022; 11(7): 1813. CrossRef - Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian
Frontiers in Medicine.2022;[Epub] CrossRef - Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease
Shana Rakowsky, Adam S. Cheifetz, Konstantinos Papamichael
Alimentary Pharmacology & Therapeutics.2021; 54(8): 1085. CrossRef
- Management of Perianal Fistulizing Crohn’s Disease
- 6,035 View
- 202 Download
- 7 Web of Science
- 7 Crossref
Editorial
- Education levels and survival in colorectal cancer: is there really an obvious association?
- Bruna Valiati, Rodrigo Oliva Perez, Paulo Gustavo Kotze
- Intest Res 2020;18(3):247-248. Published online July 20, 2020
- DOI: https://doi.org/10.5217/ir.2020.00064
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania
Edvina Elena Pîrvu, Emilia Severin, Raluca Ileana Pătru, Irina Niță, Stefania Andreea Toma, Roxana Rodica Macarie, Cristina Elena Cocioabă, Ioana Florescu, Simona Coniac
Diagnostics.2023; 13(18): 2930. CrossRef
- Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania
- 5,005 View
- 77 Download
- 2 Web of Science
- 1 Crossref
Original Article
- IBD
- Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients
- Marcello Rabello Imbrizi, Daniela Oliveira Magro, Tirzah de Mendonça Lopes Secundo, Marlone Cunha-Silva, Paulo Gustavo Kotze, Ciro Garcia Montes, Jazon Romilson de Souza Almeida, Virgínia Lúcia Ribeiro Cabral
- Intest Res 2019;17(1):63-69. Published online January 25, 2019
- DOI: https://doi.org/10.5217/ir.2018.00077
-
Abstract
PDFPubReaderePub
- Background/Aims
Inflammatory bowel disease (IBD) are chronic entities characterized by local and systemic inflammation and may be associated with thrombosis. The aim of this study was to identify the prevalence of thromboembolic events (TEE) in hospitalized IBD patients and identify risk factors for their occurrence.
Methods
This retrospective, single-center study included patients treated at a Brazilian IBD referral unit between 2004 and 2014. Patients hospitalized for more than 48 hours due to active IBD and who did not receive prophylaxis for TEE during hospitalization were included. Patients were allocated to 2 groups: those with TEE up to 30 days or at the time of hospitalization (TEE-group) and patients without TEE (control-group). Clinical and laboratory characteristics were evaluated.
Results
Of 53 patients evaluated, 69,8% with Crohn’s disease (CD) and 30.2% with ulcerative colitis (UC). The prevalence of TEE 30 days before or during hospitalization was 15.1%, with 10.8% in CD and 25% in UC. In the TEE group, mean serum albumin was 2.06 g/dL versus 3.30 g/dL in the control group. Patients with albumin levels below 2.95 g/dL (43.18%) had a higher risk of developing TEE (relative risk, 1.72; 95% confidence interval, 1.17–2.53) (P<0.001).
Conclusions
Albumin levels were significantly lower in patients with TEE, and hypoalbuminemia was considered a risk factor for the development of TEE in this population. -
Citations
Citations to this article as recorded by- Experience of primary intestinal lymphangiectasia in adults: Twelve case series from a tertiary referral hospital
Ji Eun Na, Ji Eun Kim, Sujin Park, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Dong Kyung Chang
World Journal of Clinical Cases.2024; 12(4): 746. CrossRef - Risk of venous thromboembolism with a central venous catheter in hospitalized Japanese patients with inflammatory bowel disease: a propensity score-matched cohort study
Yasuhiro Aoki, Hiroki Kiyohara, Yohei Mikami, Kosaku Nanki, Takaaki Kawaguchi, Yusuke Yoshimatsu, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Naoki Hosoe, Haruhiko Ogata, Yasushi Iwao, Takanori Kanai
Intestinal Research.2023; 21(3): 318. CrossRef - Predictors of Deep Venous Thrombosis in Hospitalized Patients With Liver Cirrhosis in the US
Ahmad Abou Yassine, Mohammad Abureesh, Rachelle Hamadi, Loai Dahabra, Mohammad Alshami, Deeb Liliane
Cureus.2022;[Epub] CrossRef - Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
Gut and Liver.2022; 16(4): 555. CrossRef - Thromboembolism is associated with poor prognosis and high mortality in patients with inflammatory bowel disease: A case–control study
Yadukrishna S., Saurabh Kedia, Varun Teja, Sudheer Kumar Vuyyuru, Nidhi Yadav, Pabitra Sahu, Saransh Jain, Dawesh P. Yadav, Sawan Bopanna, Venigalla Pratap Mouli, Deepak Madhu, Raju Sharma, Prasenjit Das, Govind Makharia, Vineet Ahuja
Indian Journal of Gastroenterology.2022;[Epub] CrossRef - Coagulation status, fibrinolysis, and platelet dynamics in dogs with chronic inflammatory enteropathy
Sara A. Jablonski Wennogle, Christine S. Olver, Sarah B. Shropshire
Journal of Veterinary Internal Medicine.2021; 35(2): 892. CrossRef - Hypoalbuminemia: a risk factor in patients with STEC-associated hemolytic uremic syndrome
Carlos J. Cobeñas, Laura L. Lombardi, Priscila Pereyra, Emanuel De Rose, María José Gogorza, Ana Paula Spizzirri, Javier D. Ruscasso, Soledad Luján Ferradas, Ángela del Carmen Suárez, Oscar R. Amoreo, Javier H. Zalba, Paula Risso
Pediatric Nephrology.2021; 36(9): 2739. CrossRef - A Conceptual Framework for Rescheduling Elective Pediatric Gastroenterology Procedures Following COVID-19 Pandemic Lockdown
Panamdeep Kaur, Thomas M. Attard, Douglas S. Fishman, Fernando Zapata, Donna Ditsch, Mike Thomson, Jennifer V. Schurman
Gastroenterology Nursing.2020; 43(5): 375. CrossRef - SURGICAL STRATEGIES IN MULTIDISCIPLINARY MANAGEMENT OF CROHN'S DISEASE
Claudio Saddy Rodrigues Coy, Paulo Gustavo Kotze
Revista Médica Clínica Las Condes.2019; 30(5): 349. CrossRef
- Experience of primary intestinal lymphangiectasia in adults: Twelve case series from a tertiary referral hospital
- 7,820 View
- 178 Download
- 9 Web of Science
- 9 Crossref
Letters to the Editor
- IBD
- The old versus the new: which do you keep in postoperative Crohn's disease?
- Paulo Gustavo Kotze, Christopher Ma, Miguel Regueiro, Remo Panaccione
- Intest Res 2018;16(2):319-320. Published online April 30, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.2.319
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Author's Reply
Sakiko Hiraoka, Jun Kato, Hiroyuki Okada
Intestinal Research.2018; 16(2): 321. CrossRef
- Author's Reply
- 5,331 View
- 57 Download
- 1 Web of Science
- 1 Crossref
Original Articles
- IBD
- Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease
- Paulo Gustavo Kotze, Daniela Oliveira Magro, Barbara Saab, Mansur Paulo Saab, Lilian Vital Pinheiro, Marcia Olandoski, Maria de Lourdes Setsuko Ayrizono, Carlos Augusto Real Martinez, Claudio Saddy Rodrigues Coy
- Intest Res 2018;16(1):62-68. Published online January 18, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.1.62
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> The use of anti-tumor necrosis factor (anti-TNF) agents seems to reduce surgical rates and delay surgical procedures in prospective trials and population-based studies in the management of Crohn's disease (CD). This study aimed to identify whether preoperative anti-TNF agents influence the time from diagnosis to surgery.
Methods An observational retrospective cohort study was conducted on patients with CD submitted to intestinal resections due to complications or medical therapy failure in a period of 7 years. The patients were allocated into 2 groups according to their previous exposure to anti-TNF agents in the preoperative period. Epidemiological aspects regarding age at diagnosis, smoking, perianal disease, and preoperative conventional therapy were considered. A Kaplan-Meier survival analysis was used to outline possible differences between the groups regarding the time to surgery.
Results A total of 123 patients were included (71 and 52 with and without previous exposure to biologics, respectively). The overall time to surgery was 108±6.9 months (maximum, 276 months). The survival estimation revealed no difference in the mean time to intestinal resection between the groups (99.78±10.62 months in the patients without and 114.01±9.07 months in those with previous anti-TNF use) (log-rank
P =0.35). There was no significant difference in the time to surgery regarding perianal CD (P =0.49), smoking (P =0.63), preoperative azathioprine (P =0.073) and steroid use (P =0.58).Conclusions The time from diagnosis to surgery was not influenced by the preoperative use of anti-TNF therapy in this cohort of patients.
-
Citations
Citations to this article as recorded by- Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America
Domingo Balderramo, Abel Botelho Quaresma, Pablo A Olivera, Mariane Christina Savio, Maria Paz Gimenez Villamil, Remo Panaccione, Siew C Ng, Gilaad G Kaplan, Paulo Gustavo Kotze
The Lancet Gastroenterology & Hepatology.2024; 9(3): 263. CrossRef - Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intestinal Research.2022; 20(1): 72. CrossRef - Establishing a rabbit model of perianal fistulizing Crohn’s disease
Shuang-Shuang Lu, Wen-Jia Liu, Qiu-Ya Niu, Chun-Yan Huo, Yu-Qing Cheng, En-Jing Wang, Rong-Nan Li, Fang-Fang Feng, Yi-Ming Cheng, Rong Liu, Jin Huang
World Journal of Gastroenterology.2022; 28(15): 1536. CrossRef - Modern surgical strategies for perianal Crohn's disease
Gilmara Pandolfo Zabot, Ornella Cassol, Rogerio Saad-Hossne, Willem Bemelman
World Journal of Gastroenterology.2020; 26(42): 6572. CrossRef - Increased prevalence of anti‐TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood
James J. Ashton, Florina Borca, Enrico Mossotto, Tracy Coelho, Akshay Batra, Nadeem A. Afzal, Hang T. T. Phan, Michael Stanton, Sarah Ennis, Robert Mark Beattie
Alimentary Pharmacology & Therapeutics.2019; 49(4): 398. CrossRef - Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn’s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study
Roy Frei, Nicolas Fournier, Jonas Zeitz, Michael Scharl, Bernhard Morell, Thomas Greuter, Philipp Schreiner, Benjamin Misselwitz, Ekaterina Safroneeva, Alain M Schoepfer, Stephan R Vavricka, Gerhard Rogler, Luc Biedermann
Journal of Crohn's and Colitis.2019; 13(10): 1292. CrossRef - Are Surgical Rates Decreasing in the Biological Era In IBD?
Francesca Di Candido, Gionata Fiorino, Marco Spadaccini, Silvio Danese, Antonino Spinelli
Current Drug Targets.2019; 20(13): 1356. CrossRef
- Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America
- 5,828 View
- 58 Download
- 8 Web of Science
- 7 Crossref
- Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease
- Daniéla Oliveira Magro, Paulo Gustavo Kotze, Carlos Augusto Real Martinez, Michel Gardere Camargo, Dioze Guadagnini, Antonio Ramos Calixto, Ana Carolina Junqueira Vasques, Maria de Lourdes Setsuko Ayrizono, Bruno Geloneze, José Carlos Pareja, Mario José Saad, Claudio Saddy Rodrigues Coy
- Intest Res 2017;15(3):352-357. Published online June 12, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.3.352
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Lipopolysaccharide (LPS) is a molecule formed by lipids and polysaccharides and is the major cell wall component of gram-negative bacteria. High LPS levels are known to block CD26 expression by activating Toll-like receptor 4. The aim of this study was to correlate the serum levels of LPS and CD26 in Crohn's disease (CD) patients with serum levels of C-reactive protein (CRP), interleukins, CD activity index, and tumor necrosis factor-α (TNF-α).
Methods Serum samples were collected from 27 individuals (10 with active CD, 10 with inactive CD, and 7 controls) and the levels of LPS, CD26, TNF-α, interleukin-1β (IL-1β), IL-6, IL-17, and CRP were determined by enzyme-linked immunosorbent assay. The levels of LPS and CD26 were then tested for correlation with TNF-α, IL-1β, IL-6, IL-17, and CRP.
Results Serum levels of LPS were significantly elevated in the active CD group (
P =0.003). Levels of IL-1β (P =0.002), IL-6 (P =0.003), and IL-17 (P <0.001) were lower in the CD groups. Serum TNF-α levels were increased in the active CD group. The CRP levels were elevated in the CD groups when compared to controls (P <0.001). The CD26 levels were lower in the CD groups than in the control group (P <0.001). Among the variables analyzed, there was a correlation between LPS and CRP (r=−0.53,P =0.016) in the CD groups.Conclusions Individuals with CD exhibited higher serum levels of LPS varying from a 2- to 6-fold increase depending on disease activity, when compared with healthy controls. CD26 levels were lower in the CD groups. Both LPS and CD26 correlated with disease severity and serve as potential CD biomarkers.
-
Citations
Citations to this article as recorded by- ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Ondřej Kučerka, Martin Malý, Petra Mináriková, Jan M. Horáček
Military Medical Science Letters.2025; 94(1): 27. CrossRef - Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
Kashif Rahim, Muhammad Shan, Ihtisham Ul Haq, Muhammad Nawaz, Sajida Maryam, Mansour Alturki, Abdulaziz Al Khzem, Kamel Metwally, Simona Cavalu, Saleh Alqifari, Galal Yahya
Journal of Inflammation Research.2024; Volume 17: 1897. CrossRef - Interaction between diet and genetics in patients with inflammatory bowel disease
Daniéla Oliveira Magro, Ligia Yukie Sassaki, Júlio Maria Fonseca Chebli
World Journal of Gastroenterology.2024; 30(12): 1644. CrossRef - Quantitative urinary proteome analysis reveals potential biomarkers for disease activity of Behcet’s disease uveitis
Weiwei Qin, Anyi Liang, Xiaoxu Han, Meifen Zhang, Youhe Gao, Chan Zhao
BMC Ophthalmology.2024;[Epub] CrossRef - Dietary fat induced chylomicron-mediated LPS translocation in a bicameral Caco-2cell model
Monic M. M. Tomassen, Coen Govers, A. Paul Vos, Nicole J. W. de Wit
Lipids in Health and Disease.2023;[Epub] CrossRef - Endothelial Glycocalyx Preservation—Impact of Nutrition and Lifestyle
Paula Franceković, Lasse Gliemann
Nutrients.2023; 15(11): 2573. CrossRef - Toll-like Receptors and Cytokine Modulation by Goat Milk Extracellular Vesicles in a Model of Intestinal Inflammation
Chiara Grazia De Ciucis, Floriana Fruscione, Livia De Paolis, Samanta Mecocci, Susanna Zinellu, Lisa Guardone, Giulia Franzoni, Katia Cappelli, Elisabetta Razzuoli
International Journal of Molecular Sciences.2023; 24(13): 11096. CrossRef - Longitudinal flux balance analyses of a patient with episodic colonic inflammation reveals microbiome metabolic dynamics
Arianna Basile, Almut Heinken, Johannes Hertel, Larry Smarr, Weizhong Li, Laura Treu, Giorgio Valle, Stefano Campanaro, Ines Thiele
Gut Microbes.2023;[Epub] CrossRef - Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice
Rachele Gore, Mitra Mohsenipour, Jennifer L. Wood, Gayathri K. Balasuriya, Elisa L. Hill-Yardin, Ashley E. Franks, Manuela Raffatellu
Infection and Immunity.2023;[Epub] CrossRef - MEFV and NLRP3 Inflammasome Expression Is Attributed to Immature Macrophages and Correlates with Serum Inflammatory Proteins in Crohn´s Disease Patients
Frida Gorreja, Charles Caër, Stephen T. A. Rush, Sophia K. Forsskål, Anetta Härtlova, Maria K. Magnusson, Elinor Bexe Lindskog, Lars G. Börjesson, Mattias Block, Mary Jo Wick
Inflammation.2022; 45(4): 1631. CrossRef - Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong
Frontiers in Immunology.2022;[Epub] CrossRef - Genetic Deletion of LRP5 and LRP6 in Macrophages Exacerbates Colitis-Associated Systemic Inflammation and Kidney Injury in Response to Intestinal Commensal Microbiota
Indumathi Manoharan, Daniel Swafford, Arulkumaran Shanmugam, Nikhil Patel, Puttur D Prasad, Riyaz Mohamed, Qingqing Wei, Zheng Dong, Muthusamy Thangaraju, Santhakumar Manicassamy
The Journal of Immunology.2022; 209(2): 368. CrossRef - The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review
Francisco Jorge Melo, Pedro Pinto-Lopes, Maria Manuela Estevinho, Fernando Magro
Inflammatory Bowel Diseases.2021; 27(7): 1153. CrossRef - Effects of Anthocyanin on Intestinal Health: A Systematic Review
Thaísa Agrizzi Verediano, Hércia Stampini Duarte Martino, Maria Cristina Dias Paes, Elad Tako
Nutrients.2021; 13(4): 1331. CrossRef - Anti-inflammatory activity of Jasminum grandiflorum L. subsp. floribundum (Oleaceae) in inflammatory bowel disease and arthritis models
Riham A. El-Shiekh, Dorria Hussein, Attia H. Atta, Samar M. Mounier, Mohamed R. Mousa, Essam Abdel-Sattar
Biomedicine & Pharmacotherapy.2021; 140: 111770. CrossRef - Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
Jasmijn A. M. Sleutjes, Jeanine E. Roeters van Lennep, C. Janneke van der Woude, Annemarie C. de Vries
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef - Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease
Sabrina A Fernandes, Carina Rossoni, Vivian W Koch, Marcello Imbrizi, Rosana Evangelista-Poderoso, Letícia Pereira Pinto, Daniéla Oliveira Magro
Artificial Intelligence in Gastroenterology.2021; 2(4): 111. CrossRef - Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA
Aristo Vojdani, Elroy Vojdani, Martha Herbert, Datis Kharrazian
International Journal of Molecular Sciences.2020; 21(4): 1381. CrossRef - CD26/DPP4 - a potential biomarker and target for cancer therapy
Njanja Enz, Gwendolyn Vliegen, Ingrid De Meester, Wolfgang Jungraithmayr
Pharmacology & Therapeutics.2019; 198: 135. CrossRef - Is there a possible correlation between antibodies against lipopolysaccharide, intestinal and blood-brain barrier proteins in IBD subjects?
Aristo Vojdani
Autoimmunity Reviews.2019; 18(6): 639. CrossRef - CD26 in autoimmune diseases: The other side of “moonlight protein”
Yunjuan Zhao
International Immunopharmacology.2019; 75: 105757. CrossRef - Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production
Daniéla Oliveira Magro, Andrey Santos, Dioze Guadagnini, Flavia Moreira de Godoy, Sylvia Helena Monteiro Silva, Wilson José Fernandes Lemos, Nicola Vitulo, Sandra Torriani, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Mario José Abdalla Saad, Clau
Scientific Reports.2019;[Epub] CrossRef - Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults
Tiansheng Wang, Jeff Y. Yang, John B. Buse, Virginia Pate, Huilin Tang, Edward L. Barnes, Robert S. Sandler, Til Stürmer
Diabetes Care.2019; 42(11): 2065. CrossRef - Emerging concepts in non-invasive monitoring of Crohn’s disease
Wojciech Marlicz, Karolina Skonieczna-Żydecka, Konstantinos John Dabos, Igor Łoniewski, Anastasios Koulaouzidis
Therapeutic Advances in Gastroenterology.2018;[Epub] CrossRef - VISCERAL FAT IS INCREASED IN INDIVIDUALS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS WITH HEALTHY CONTROLS
Daniéla Oliveira MAGRO, Maria Rita Lazzarini BARRETO, Everton CAZZO, Michel Gardere CAMARGO, Paulo Gustavo KOTZE, Claudio Saddy Rodrigues COY
Arquivos de Gastroenterologia.2018; 55(2): 142. CrossRef
- ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
- 6,831 View
- 55 Download
- 24 Web of Science
- 25 Crossref
Review
- Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
- Paulo Gustavo Kotze, Subrata Ghosh, Willem A. Bemelman, Remo Panaccione
- Intest Res 2017;15(2):160-165. Published online April 27, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.2.160
-
Abstract
PDFPubReaderePub
Recent advances in medical and surgical therapy were achieved during the last two decades in the management of Crohn's disease (CD). Anti-tumor necrosis factor (anti-TNF) agents are widely used worldwide. However, a significant proportion of patients still need surgical resections. The impact of previous exposure to these agents on the perioperative and postoperative outcomes is still controversial. In this critical review, we aimed to position the strategy of intentional preoperative use of anti-TNF agents in the management of CD. The indications and contraindications for this strategy are detailed, and despite scarce evidence, the possible advantages and disadvantages of the intentional use of anti-TNF agents before abdominal surgery in CD are discussed.
-
Citations
Citations to this article as recorded by- Clinical guidelines. Crohn’s disease (К50), adults
Yury A. Shelygin, Vladimir T. Ivashkin, Sergey I. Achkasov, Igor V. Reshetov, Igor V. Maev, Elena A. Belousova, Armen V. Vardanyan, Bella A. Nanaeva, Leila V. Adamyan, Oksana M. Drapkina, Leila S. Namazova-Baranova, Aleksandr Yu. Razumovsky, Amiran Sh. Re
Koloproktologia.2023; 22(3): 10. CrossRef - Surgical Management of Small Bowel Crohn's Disease
Pramodh Chandrasinghe
Frontiers in Surgery.2022;[Epub] CrossRef - Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review
Abel Botelho Quaresma, Fernanda da Silva Barbosa Baraúna, Fábio Vieira Teixeira, Rogério Saad-Hossne, Paulo Gustavo Kotze
Journal of Clinical Medicine.2021; 10(4): 710. CrossRef - The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn’s Disease
Amy L. Lightner, Jon D. Vogel, Joseph C. Carmichael, Deborah S. Keller, Samir A. Shah, Uma Mahadevan, Sunanda V. Kane, Ian M. Paquette, Scott R. Steele, • Daniel L. Feingold
Diseases of the Colon & Rectum.2020; 63(8): 1028. CrossRef - Enterocutaneous fistula in severely active Crohn’s disease: preoperative anti-TNF alpha treatment to limit bowel resection—report of a case
Peter Wilhelm, Andreas Kirschniak, Jonas Johannink, Sascha Kaufmann, Thomas Klag, Jan Wehkamp, Claudius Falch
International Journal of Colorectal Disease.2019; 34(2): 369. CrossRef - Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries
Tawnya M Hansen, Laura E Targownik, Ahmer Karimuddin, Yvette Leung
Inflammatory Bowel Diseases.2019; 25(10): 1613. CrossRef - Gestion périopératoire des biothérapies en 2019
Thibault Martinez, Jean Derely, Astrée Swiech, Gaël de Roquigny, Charlotte Delattre, Frederic Banal, Mehdi Ould-Ahmed, Diane Commandeur
Anesthésie & Réanimation.2019; 5(4): 274. CrossRef - Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives
Alaa El-Hussuna, Pär Myrelid, Stefan D Holubar, Paulo G Kotze, Graham Mackenzie, Gianluca Pellino, Des Winter, Justin Davies, Ionut Negoi, Perbinder Grewal, Gaetano Gallo, Kapil Sahnan, Ines Rubio-Perez, Daniel Clerc, Nicolas Demartines, James Glasbey, Mi
Crohn's & Colitis 360.2019;[Epub] CrossRef - Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
Paulo Gustavo Kotze, Christopher Ma, Nicholas Mckenna, Abdulelah Almutairdi, Gilaad G. Kaplan, Laura E. Raffals, Edward V. Loftus, Remo Panaccione, Amy L. Lightner
Therapeutic Advances in Gastroenterology.2018;[Epub] CrossRef - Emerging Therapies: What Are Promising in the Near Future?
Geom Seog Seo, Sung Hee Lee
The Korean Journal of Gastroenterology.2018; 71(2): 81. CrossRef - Perioperative Care of Patients with Inflammatory Bowel Disease: Focus on Nutritional Support
Patrick L. Stoner, Amir Kamel, Fares Ayoub, Sanda Tan, Atif Iqbal, Sarah C. Glover, Ellen M. Zimmermann
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
- Clinical guidelines. Crohn’s disease (К50), adults
- 6,123 View
- 61 Download
- 9 Web of Science
- 11 Crossref
Original Article
- Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn's Disease: an International, Multicenter, and Observational Study
- Paulo Gustavo Kotze, Antonino Spinelli, Rodolff Nunes da Silva, Ivan Folchini de Barcelos, Fábio Vieira Teixeira, Rogério Saad-Hossne, Idblan Carvalho de Albuquerque, Marcia Olandoski, Lorete Maria da Silva Kotze, Yasuo Suzuki, Akihiro Yamada, Ken Takeuchi, Matteo Sacchi, Takayuki Yamamoto
- Intest Res 2015;13(3):259-265. Published online June 9, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.3.259
-
Abstract
PDFPubReader
<b>Background/Aims</b><br/> Postoperative endoscopic recurrence (PER) occurs in nearly 80% of patients 1 year after ileocecal resection in patients with Crohn's disease (CD). Biological agents were more effective in reducing the rates of PER in comparison with conventional therapy, in prospective trials. The aim of this study was to compare the PER rates of biological versus conventional therapy after ileocecal resections in patients with CD in real-world practice.
Methods The MULTIPER (Multicenter International Postoperative Endoscopic Recurrence) database is a retrospective analysis of PER rates in CD patients after ileocecal resection, from 7 referral centers in 3 different countries. All consecutive patients who underwent ileocecal resections between 2008 and 2012 and in whom colonoscopies had been performed up to 12 months after surgery, were included. Recurrence was defined as Rutgeerts' score ≥i2. The patients were allocated to either biological or conventional therapy after surgery, and PER rates were compared between the groups.
Results Initially, 231 patients were evaluated, and 63 were excluded. Of the 168 patients in the database, 96 received anti-tumor necrosis factor agents and 72 were treated with conventional therapy after resection. The groups were comparable regarding age, gender, and perianal disease. There was longer disease duration, more previous resections, and more open surgical procedures in patients on biologicals postoperatively. PER was identified in 25/96 (26%) patients on biological therapy and in 24/72 (33.3%) patients on conventional therapy (
P =0.310).Conclusions In this retrospective observational analysis from an international database, no difference was observed between biological and conventional therapy in preventing PER after ileocecal resections in CD patients.
-
Citations
Citations to this article as recorded by- Are the New Biologics Effective in the Management of Postoperative Crohn’s Disease?
Fadi H Mourad, Rami G Maalouf, Roni Aoun, Paulo Gustavo Kotze, Jana G Hashash
Inflammatory Bowel Diseases.2024; 30(3): 459. CrossRef - How Reliable Is Endoscopic Scoring of Postoperative Recurrence in Crohn Disease?: A Systematic Review and Meta-Analysis
Eline M. L. van der Does de Willebois, Vittoria Bellato, Marjolijn Duijvestein, Susan van Dieren, Silvio Danese, Pierpaolo Sileri, Christianne J. Buskens, Andrea Vignali, Willem A. Bemelman
Annals of Surgery Open.2024; 5(1): e397. CrossRef - Trends in Surgical Recurrence Among Pediatric Crohn’s Disease Patients Using Administrative Claims Data
Matthew D Egberg, Xian Zhang, Michael Phillips, Michael D Kappelman
Crohn's & Colitis 360.2023;[Epub] CrossRef - Optimal strategies to prevent recrudescent Crohn's disease after resection
Natália Sousa Freitas Queiroz, Takayuki Yamamoto, Paulo Gustavo Kotze
Seminars in Colon and Rectal Surgery.2020; 31(2): 100746. CrossRef - Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn’s Disease
Ruiqing Liu, Zhen Guo, Lei Cao, Zhiming Wang, Jianfeng Gong, Yi Li, Weiming Zhu
Diseases of the Colon & Rectum.2019; 62(3): 318. CrossRef - Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
Sakiko Hiraoka, Shiho Takashima, Yoshitaka Kondo, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Seiji Kawano, Keita Harada, Jun Kato, Hiroyuki Okada
Intestinal Research.2018; 16(1): 75. CrossRef - Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study
I. F. de Barcelos, P. G. Kotze, A. Spinelli, Y. Suzuki, F. V. Teixeira, I. C. de Albuquerque, R. Saad‐Hossne, L. M. da Silva Kotze, T. Yamamoto
Colorectal Disease.2017;[Epub] CrossRef - Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study
Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2016; 10(4): 595. CrossRef
- Are the New Biologics Effective in the Management of Postoperative Crohn’s Disease?
- 5,810 View
- 55 Download
- 7 Web of Science
- 8 Crossref
Letters to the Editor
- Endoscopic Postoperative Recurrence Rates in Crohn's Disease in Korea: The Beginning of a New Approach?
- Paulo Gustavo Kotze, Rogerio Saad-Hossne, Antonino Spinelli
- Intest Res 2014;12(3):258-259. Published online July 25, 2014
- DOI: https://doi.org/10.5217/ir.2014.12.3.258
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
Sakiko Hiraoka, Shiho Takashima, Yoshitaka Kondo, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Seiji Kawano, Keita Harada, Jun Kato, Hiroyuki Okada
Intestinal Research.2018; 16(1): 75. CrossRef - Author's Reply
Kang-Moon Lee
Intestinal Research.2014; 12(3): 260. CrossRef
- Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
- 9,449 View
- 28 Download
- 2 Web of Science
- 2 Crossref
Review
- Biological Therapy for the Prevention and Treatment of Postoperative Endoscopic Recurrence in Crohn's Disease: Time for Acceptance?
- Paulo Gustavo Kotze, Rogério Saad-Hossne
- Intest Res 2013;11(4):256-260. Published online October 30, 2013
- DOI: https://doi.org/10.5217/ir.2013.11.4.256
-
Abstract
PDF
- In most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn's disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD. (Intest Res 2013;11:256-260)
-
Citations
Citations to this article as recorded by- Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease
Tsubasa Oike, Naoki Akizue, Yuki Ohta, Hirotaka Koseki, Masaya Saito, Yuya Yokoyama, Yushi Imai, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Sadahisa Ogasawara, Tomoaki Matsumura, Tomoo Nakagawa, Makoto Arai, Tatsuro Katsuno, Yoshihiro Fukuda, Yoshio K
Arab Journal of Gastroenterology.2024; 25(3): 257. CrossRef - Gastric lesions in patients with Crohn's disease in Korea: a multicenter study
Hoonsub So, Byong Duk Ye, Young Soo Park, Jihun Kim, Joo Sung Kim, Won Moon, Kang-Moon Lee, You Sun Kim, Bora Keum, Seong-Eun Kim, Kyeong Ok Kim, Eun Soo Kim, Chang Kyun Lee, Sung Pil Hong, Jong Pil Im, Ja Seol Koo, Chang Hwan Choi, Jeong Eun Shin, Bo In
Intestinal Research.2016; 14(1): 60. CrossRef - Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung, Dong Il Park, Young Ho Kim, Ji Hyun Lee, Pyoung Ju Seo, Jae Hee Cheon, Hyoun Woo Kang, Ji Won Kim
Journal of Gastroenterology and Hepatology.2015; 30(12): 1705. CrossRef - Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn's Disease: an International, Multicenter, and Observational Study
Paulo Gustavo Kotze, Antonino Spinelli, Rodolff Nunes da Silva, Ivan Folchini de Barcelos, Fábio Vieira Teixeira, Rogério Saad-Hossne, Idblan Carvalho de Albuquerque, Marcia Olandoski, Lorete Maria da Silva Kotze, Yasuo Suzuki, Akihiro Yamada, Ken Takeuch
Intestinal Research.2015; 13(3): 259. CrossRef - Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
Sang Hyoung Park, Young-Ho Kim, Ji Hyun Lee, Hyeok Jin Kwon, Suck-Ho Lee, Dong Il Park, Hyung Kil Kim, Jae Hee Cheon, Jong Pil Im, You Sun Kim, Sung Young Lee, Sang Joon Lee
Expert Review of Gastroenterology & Hepatology.2015; 9(sup1): 35. CrossRef - What is the Important Issue to Prevent the Postoperative Crohn's Disease?
You Sun Kim
Intestinal Research.2014; 12(2): 85. CrossRef - Author's Reply
Kang-Moon Lee
Intestinal Research.2014; 12(3): 260. CrossRef
- Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease
- 2,811 View
- 17 Download
- 7 Crossref
First
Prev
